Bone Resorption

Subscribe to Selected New Research on Bone Resorption

9263 relevant articles (292 outcomes, 981 trials/studies) found for this Disease

Description: Bone loss due to osteoclastic activity.

Also Known As:

Bone Losses, Osteoclastic; Bone Resorptions; Loss, Osteoclastic Bone; Losses, Osteoclastic Bone; Osteoclastic Bone Losses; Resorption, Bone; Resorptions, Bone; Bone Loss, Osteoclastic; Osteoclastic Bone Loss

Relationship Network

Disease Context: Research Results

Musculoskeletal Diseases: 87

Bone Diseases: 2533

Bone Resorption: 9263

Osteolysis: 1689

Alveolar Bone Loss: 340

Ainhum: 10

Musculoskeletal and Neural Physiological Phenomena

Musculoskeletal Physiological Phenomena

Musculoskeletal Physiological Processes

Bone Remodeling

Bone Resorption: 9263

Osteolysis: 1689

Related Diseases

1.	Osteoporosis
2.	Neoplasm Metastasis (Metastasis)
3.	Neoplasms (Cancer)
4.	Hypercalcemia (Milk Alkali Syndrome)
5.	Pain (Aches)

Experts

1.	Kim, Hong-Hee: 7 articles (09/2008 - 04/2004)
2.	Kim, Cheorl-Ho: 7 articles (04/2008 - 08/2003)
3.	Lee, Zang Hee: 6 articles (09/2008 - 04/2004)
4.	Garnero, P: 5 articles (04/2008 - 01/2001)
5.	Väänänen, H Kalervo: 5 articles (04/2006 - 01/2002)
6.	Tanaka, Sakae: 4 articles (09/2008 - 12/2005)
7.	Yamaguchi, Masayoshi: 4 articles (08/2008 - 03/2003)
8.	Hara, Y: 4 articles (06/2008 - 02/2001)
9.	Schwarz, Edward M: 4 articles (05/2008 - 05/2002)
10.	Kwak, Han Bok: 4 articles (09/2007 - 04/2004)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Bone Resorption:

1.	DiphosphonatesIBA 01/01/2005 - "Bisphosphonates are proven to be effective in the treatment of benign or malignant skeletal diseases characterized by enhanced osteoclastic bone resorption. " 08/30/2000 - "BACKGROUND: Bisphosphonates are potent inhibitors of osteoclast-mediated bone resorption and effective in preventing osteoporotic fractures, but they can occasionally cause oesophageal adverse events. " 09/01/1998 - "Bisphosphonates (BPs) are potent inhibitors of bone resorption and are therapeutically effective in disease of increased bone turnover, but their mechanism(s) of action remain to be elucidated. " 10/01/1993 - "The general availability of an ever-expanding range of increasingly potent bisphosphonates has resulted in a dramatic improvement in the treatment of increased bone resorption associated with malignancy. " 09/01/1992 - "Better understanding of the mechanisms underlying tumour-induced bone resorption and development of more potent and less toxic bisphosphonates will lead to improved management of patients with malignant diseases involving the skeleton." Order ALL the reference details at left...
2.	CalciumIBA 11/01/2002 - "Adding three servings of yogurt to the daily diet of older women with habitually low calcium intakes resulted in a significant reduction in urinary excretion of N-telepeptide, a marker for bone resorption. " 05/01/1982 - "After short-term therapy (6-8 months), calcium absorption was normal (27 +/- 3%, P less than 0.001 for difference from base line), calcium balance had improved (+2 +/- 26 mg/day, P less than 0.05), and bone resorption rate (195 +/- 35 mg/day, P less than 0.01) had decreased more than bone formation rate (197 +/- 26 mg/day, NS). " 06/01/1991 - "There was evidence of an immediate reduction in bone resorption, with increased calcium absorption (delayed in Patient 1), improved calcium balance and maintained or improved bone density indices in the axial and peripheral skeleton. " 05/01/1975 - "Under treatment the calcium balance improved, due predominantly to a decrease in bone resorption associated with an increase in bone accretion and intestinal absorption of calcium. " 12/01/2009 - "Low calcium intake is associated with increased bone resorption in postmenopausal Japanese women: Yokogoshi Study." Order ALL the reference details at left...
3.	pamidronate (APD)FDA LinkGeneric 10/01/1989 - "Dimethyl-APD therapy was highly effective in inhibiting bone resorption. " 01/01/1989 - "Dichloromethylene bisphosphonate and aminobisphosphonate, especially APD, were shown to inhibit bone resorption with no noticeable inhibition of bone formation, and were highly effective in the long-term treatment of Paget's disease. " 04/01/2002 - "This report describes a case of refractory HPOA with complete remission following the administration of IV pamidronate, which is a potent inhibitor of osteoclastic bone resorption. " 08/01/1988 - "CONCLUSION: Due to the important and sustained inhibition of bone resorption induced by AHPrBP, a single infusion of 60 mg of the bisphosphonate leads to a rapid decline in activity and a long-standing remission of moderate Paget's disease, without significant side effects." 01/01/1997 - "Pamidronate seems to be more effective in inhibiting bone resorption in bone that undergoes rapid turnover (i.e. " Order ALL the reference details at left...
4.	deoxypyridinolineIBA 05/01/2008 - "Furthermore, markers of osteoclastic bone resorption, including osteoclast number, osteoclast surface, and urinary deoxypyridinoline excretion, were again significantly greater only in the triply NOS(-/-) mice. " 02/01/2002 - "Urinary deoxypyridinoline, an index of bone resorption, was significantly greater in TS rats, but unaltered by (-)Cu. " 01/01/2009 - "PURPOSE: Deoxypyridinoline (DPD) is a derivative of hydroxypyridinium, which is released during bone resorption into the blood stream and is eliminated unmodified with urine. " 10/01/1994 - "We now describe the development of an immunoassay (ELISA) based on a monoclonal antibody for free deoxypyridinoline (Dpd) and its use in healthy individuals and patients with bone-related disorders to measure the urinary excretion of Dpd as an improved assessment of bone resorption rate. " 09/01/2008 - "Femur bone density decreased, and urinary excretion of deoxypyridinoline, an index of bone resorption capacity of osteoclasts, increased in ovariectomized animals at the end of the study. " Order ALL the reference details at left...
5.	Biological Markers (Surrogate Marker)IBA 05/01/2008 - "Since the anti-fracture efficacy of inhibitors of bone resorption or stimulators of bone formation appears to be largely independent of baseline bone turnover, biochemical markers do not appear to play a significant role in the selection of one particular drug, for an individual patient. " 10/01/2001 - "Treatment with SB-357114 (12 mg/kg subcutaneously) resulted in a significant reduction in serum markers of bone resorption relative to untreated controls. " 04/16/1997 - "Efficacy of both the treatment can be assessed after 6 months using a biochemical marker of bone resorption and after 2 years using dual-energy x-ray densitometry." 11/01/2009 - "Initial studies have shown good agreement between the 3 methods of measuring K(bone), and highly significant correlations between the change in K(bone) values during treatment and the corresponding changes in serum and urinary measurements of biochemical markers of bone formation and bone resorption." 02/01/2009 - "Study parameters were plasma CT levels measured up to 2 hours postdose and changes in the bone resorption marker serum CTX-I and the cartilage degradation marker urine CTX-II measured up to 4 hours postdose. " Order ALL the reference details at left...
6.	Alendronate (Alendronate Sodium)FDA LinkGeneric 05/01/2000 - "BACKGROUND: The present study was designed to examine histopathologically whether local delivery of aminobisphosphonate (alendronate) could be effective in preventing the alveolar bone resorption associated with mucoperiosteal flaps. " 01/01/2001 - "Alendronate sodium (Fosamax) is a commonly used antiresorptive agent effective in osteopenic women for reducing bone resorption, increasing bone density, and decreasing fracture incidence. " 08/01/2007 - "Treatment with alendronate improved trabecular volume and number by reducing bone resorption, although bone formation was also reduced through coupling of bone remodeling. " 01/01/2009 - "METHODS: We examined 51 bone-biopsy specimens obtained after a 3-year, double-blind, randomized, placebo-controlled, dose-ranging trial of oral alendronate to prevent bone resorption among healthy postmenopausal women 40 through 59 years of age. " 07/01/2007 - "For this reason, we conducted a study to test the effect of alendronate (ALN), an inhibitor of bone resorption, on alveolar bone mass. " Order ALL the reference details at left...
7.	Alkaline PhosphataseIBA 01/01/2009 - "Although bone resorption markers gradually decreased throughout the study period, bone alkaline phosphatase significantly increased during the first 4 weeks and then gradually decreased. " 04/01/2009 - "Postmenopausal women treated with an isopropanolic extract of Cimicifuga racemosa underwent a decrease in the urinary concentration of N-telopeptides, a marker of bone resorption, and an increase in alkaline phosphatase, a marker of bone formation, at the third month of therapy. " 05/01/2008 - "Bone turnover was greatly accelerated by RANKL, as evidenced by the 49-84% greater levels of serum TRAP-5b (bone resorption marker) and 300-400% greater levels of serum alkaline phosphatase (bone formation marker). " 01/01/2008 - "Bone resorption could result in a compensatory osteoblast activation indicated by an increase in serum alkaline phosphatase (sAP). " 09/01/2005 - "Markers of bone formation and bone resorption included plasma total alkaline phosphatase and urine N-telopeptides. " Order ALL the reference details at left...
8.	Vitamin D FDA LinkGeneric 09/01/2003 - "These material properties, together with indications of decreased bone resorption in secondary spongiosa and increased cortical periosteal bone formation, appear to contribute to the improved mechanical properties of their long bones and suggest an important physiological role of the vitamin D-endocrine system in normal bone mineralization." 04/01/1997 - "Also the vitamin D-supplemented animals exhibited significantly greater levels of bone resorption. " 11/01/2008 - "Studies in hypercalciuric TRPV5 knockout (TRPV5(-/-)) mice, which display significantly increased vitamin D levels, showed that TRPV5 ablation increases number and size of osteoclasts but impairs osteoclast-mediated bone resorption. " 05/01/2004 - "In this population-based study, seasonal periodicity was seen with reduced serum vitamin D, increased serum PTH, and increased bone resorption in winter. " 11/01/2001 - "The importance of these studies in the rat model is that they identify a class of drugs in current clinical use that can be used to treat patients with vitamin D toxicity and that they identify the dose of the drug that is predicted to be effective, namely the dose that inhibits bone resorption. " Order ALL the reference details at left...
9.	Collagen Type I (Type I Collagen)IBA 05/01/1999 - "The urinary amino-terminal (NTXtrade mark) and carboxy-terminal (CrossLapstrade mark) cross-linked fragments of type I collagen, both markers of bone resorption, showed a marked decrease (25-50%) with both regimens during the period of active treatment. " 01/01/2001 - "A significant reduction in C-terminal telopeptide type 1 collagen (1CTP) indicated decreased bone resorption 1 year after surgery (p < 0.05). " 02/09/2004 - "Although not optimized, a selected inhibitor was effective in attenuating type I collagen hydrolysis in a surrogate assay of bone resorption." 12/01/2001 - "An ELISA procedure was developed to evaluate the efficacy of this monoclonal to measure bone resorption and characterize urinary degradation products of C-terminal type I collagen. " 12/01/2004 - "The effect of storage temperature on stability of bone resorption markers have not been subject of systematically investigation, and therefore the present study was set out to determine the stability of C-telopeptides of type I collagen (CTX) in serum and plasma samples stored frozen for 3 years. " Order ALL the reference details at left...
10.	pyridinolineIBA 11/01/1992 - "The method shows considerable promise as a rapid and specific index of human bone resorption rates, with greatly improved specificity and convenience over total pyridinoline analysis. " 11/24/2000 - "Femur weights and serum concentrations of pyridinoline, a reliable marker of bone resorption, were measured at the end of the study period. " 08/01/2002 - "Bone resorption was assessed by measuring the urinary concentrations of pyridinoline and deoxypiridinoline. " 05/01/2002 - "High levels of urinary pyridinoline crosslinks in the oim/oim;Tg/Tg mice were present at all ages, reflecting continuing high bone resorption. " 03/01/2002 - "3. Plasma pyridinoline concentration was higher in hens in the low BI line, suggesting a greater rate of bone resorption in this line. " Order ALL the reference details at left...

Therapies and Procedures

1.	Transplants (Transplant) 04/01/2003 - "The process of photooxidation decreased the speed of bone resorption in osteochondral grafts and, thus, improved graft stability and cartilage survival. " 10/01/1987 - "Toothless is an osteopetrotic mutation in the rat characterized by reduced bone resorption, few osteoclasts and failure to be cured by bone marrow transplants from normal littermates. " 03/01/2009 - "Some studies reveal that the transplant is associated with subchondral bone resorption, often leading to deep pits beneath the presumptive cartilage repair site. " 06/01/2007 - "CONCLUSION: The results of this study suggest that an onlay osseous graft protected by a Ti-Mesh demonstrated significantly less bone resorption when compared with an onlay bone graft alone. " 08/01/1999 - "The objective of the present report was to study the effects of barrier membranes on bone resorption and implant stability in a rabbit onlay bone graft model, using resonance frequency analysis, coordinate measurements on plaster models, removal torque measurements and histology. " Order ALL the reference details at left...
2.	Ovariectomy (Oophorectomy) 05/01/2004 - "The results of this study emphasize that oil extract of garlic possibly has a positive role in suppressing ovariectomy-induced bone resorption." 02/01/1994 - "The present study thus indicates that an increase of bone resorption which was evaluated by urinary HP and LP occurs in the early stage after oophorectomy. " 12/01/1991 - "In previous studies, we have shown that ovariectomy accelerates bone resorption and 1-hydroxyethylidene-1, 1-bisphosphonate (HEBP) inhibits ovariectomy-accelerated bone resorption in female Wistar adult rats. " 01/01/1989 - "Women with increased bone resorption induced by bilateral oophorectomy 1-5 years previously (of a total of 48 women in the study, 20 were controls, and 28 were the treatment group) were studied during a 3 year follow-up. " 01/01/2009 - "Onion has been reported to decrease the ovariectomy-induced bone resorption. " Order ALL the reference details at left...
3.	Injections 01/01/1989 - "In the present study, rats were pretreated with either 1-hydroxyethylidene-1, 1-bisphosphonate (HEBP, 10 mg/kg.day sc), with prevailing inhibitory action on bone mineral formation, or dichloromethylene bisphosphonate (Cl2MBP, 10 mg p/kg.day sc) with prevailing action on bone resorption, or NaCl injections (controls) for 7 days. " 06/01/2009 - "We histomorphometrically evaluated bone resorption at sites of T cell injections and examined the influence of T cells from LPS-immunized mice on osteoclastogenesis in vitro. " 03/01/2006 - "Alveolar bone resorption in normal mice, in SCID mice that lack both B and T cells, and in B cell-reconstituted SCID mice was compared histopathologically after repeated injections of lipopolysaccharide (LPS) into the gingiva. " 01/01/2004 - "In animal models OPG prevents bone loss, and in humans bone resorption can be reduced by injections of OPG. " 06/01/2003 - "Bone resorption markers were significantly reduced during the injection period, but returned to baseline levels after the injections were stopped. " Order ALL the reference details at left...
4.	Tooth Movement 05/01/2004 - "Thus, 1,25-DHCC was found to be more effective in modulating bone turnover during orthodontic tooth movement, because its effects on bone formation and bone resorption were well balanced." 08/01/2009 - "Further, OPG was locally present in excess amounts over RANKL and an increased RANKL/OPG in the study groups could be correlated with an increased bone resorption activity during orthodontic tooth movement." 09/01/1994 - "The purpose of this study was to examine the effect of 4-amino-1-hydroxybutylidene-1,1-bisphosphonate (AHBuBP), a potent blocker of bone resorption, on orthodontic tooth movements in rats. " 07/01/1991 - "This study was undertaken to investigate the stress-strain levels and distribution within the periodontal ligament for various types of physiological and orthodontic force systems, assuming that the bone resorption process, leading to tooth movements, is partly controlled by those conditions. " 01/01/1973 - "Histologic and histometric study of bone resorption after tooth movement in rats." Order ALL the reference details at left...
5.	Intravenous Infusions 01/01/1991 - "We conclude that ABDP is a highly potent diphosphonate and that a single intravenous infusion is capable of inhibiting tumour-mediated bone resorption for several days." 09/01/2003 - "The bisphosphonates inhibit osteoclastic bone resorption and have been used as an intravenous infusion in fibrous dysplasia of the bone. " 10/15/1997 - "These initial human data suggest that zoledronate can be administered as convenient short intravenous infusions and lead to a more marked and a more prolonged inhibition of bone resorption than is currently possible with available compounds. " 09/01/1992 - "Alendronate (aminohydroxybutylidene bisphosphonate) is a potent inhibitor of bone resorption but the role of the duration of intravenous infusion in its efficacy profile is unclear. " 12/01/2002 - "Cyclical intermittent intravenous infusions of pamidronate, a potent inhibitor of bone resorption, have yielded substantial improvement in chronic pain, bone mineral density, fracture rate and mobility without significant side effects. " Order ALL the reference details at left...

Best Treatments:
Research Summary Report
on Bone Resorption

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 292 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>